ClinicalTrials.gg
RecruitingNCT06996951Updated Nov 10, 2026

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

A Phase 3 interventional study of STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID and CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID in Cystic Fibrosis (CF) and Chronic Rhinosinusitis (CRS), sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Indiana University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 10, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Planned enrollment
170th of 517
64 · median 36
Started
2025
with 19 others
Phase 3
100 of 717
2 open now
Primary completion
2027-07
later than 57 of 108 live
Registered
691st of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 170th largest by planned enrollment of the 517 interventional ones that give a count, is one of 20 that started in 2025, is one of 100 in phase 3, reaches primary completion later than 57 of the 108 other live ones, and was the 691st registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The investigators are doing this study to discover if it is appropriate for people with Cystic Fibrosis (CF) on highly effective modulator therapy (HEMT) to stop using certain standard Sino nasal therapies such as high-volume nasal saline irrigations, topical nasal steroids, and topical nasal antibiotics. They are also going to study the fluid inside the nose to see if there are changes when stopping these therapies. Right now, they are not sure if it is suggested to stop these treatments when patients begin highly effective modulator therapy (HEMT)

Read the detailed description

Cystic fibrosis (CF) is a widely known genetic disorder causing patients significant sinopulmonary disease. (1) The advent of highly effective modulator therapy (HEMT) has led to tremendous improvements in manifestations of disease in the lungs, sinuses, along with other organ systems, raising the question of whether and how to de-escalate other treatments for the airways. Specifically for CF, no protocols exist for the de-escalation of the most common sinonasal therapies: high-volume nasal saline irrigations, topical nasal steroids, and topical nasal antibiotics. Establishing such protocols would benefit patients by removing these cumbersome medication regimens, reducing the cost of medications, and lowering risks of side effects and complications from therapies that may no longer provide clinical benefit. This study aims to sample the sinonasal environment for inflammatory markers in patients with cystic fibrosis (PwCF )on HEMT and correlate to subjective and objective clinical findings during de-escalation trials from saline nasal irrigations, topical nasal steroids and/or antibiotics.

The investigators will prospectively follow adult cystic fibrosis patients with chronic rhinosinusitis with or without history of sinus surgery currently using CFTR modulator therapy via diagnostic methods (nasal endoscopy, FEV1, BMI) which are standard of care evaluations currently performed at both Rhinologic and Pulmonary visits. Questions regarding health care utilization (antibiotics, steroids, hospital admissions, doctor visits) will be reviewed, which are also part of the standard history taken at patient intake for these visits. Patient reported outcome measures (PROMS) (SNOT-22, Cystic Fibrosis Questionnaire- Revised (CFQ-R), Patient Health Questionnaire-9 (PHQ-9)) are also routinely collected at these Rhinologic and Pulmonary visits, thus patients are accustomed to these items in routine standard of care followups. Upon enrollment to the study after informed consent obtained, the patients will be randomly assigned to continue or stop topical medicated nasal irrigations. Participants will continue the 1-2 times per day they currently perform the saline topical nasal irrigations, or told to discontinue completely.

To better understand the inflammatory microenvironment on and off HEMT therapy, nasal leukosorb analyses will be studied from at 4-week intervals in the PwCF enrolled in aim 1 for the 12-week study period, to determine trends of inflammation for patients in each arm of the de-escalation study. Following protocols established by Rebuli et al, patients will moisten their nostrils with \~100uL of 0.9% sterile normal saline solution, followed by applying a cut sheet of Leukosorb medium of 4x40mm in length into each nostril onto the anterior part of the inferior turbinate. (19) The nostrils will then be clamped with a padded nose clip. The strips will be removed at 2 minutes, and placed into 1.5mL collection tubes and stored at -20 deg C until fluid elution and analysis.

03

Conditions studied

  • Cystic Fibrosis (CF)
  • Chronic Rhinosinusitis (CRS)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Cystic Fibrosis diagnosis on HEMT
  • History of chronic rhinosinusitis
  • Using topical nasal irrigations +/- additives (, antibiotics)

Exclusion criteria

Exclusion Criteria:

  • Below age of 18 years old
  • Cystic Fibrosis patient NOT on highly effective modulator therapy
  • Pregnant patients
  • Not currently using topical nasal irrigations +/- additives (, antibiotics)
  • History of sinonasal or nasopharyngeal tumors
  • Active sinonasal infection or pulmonary infection
  • Admission to hospital for pulmonary exacerbation within last 3 months
  • Oral antibiotics within last one month for upper respiratory or lower respiratory infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    CONTINUE TOPICAL STEROID NASAL IRRIGATION

    PARTICIPANTS WILL CONTINUE THEIR NASAL TREATMENT WHICH WAS ALREADY PRESCRIBED BY THEIR PHYSICIAN

    Drug: CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

  • Experimental
    STOP TOPICAL NASAL TREATMENT

    PARTICIPANTS IN THIS ARM WILL BE ASKED TO STOP THEIR NASAL TREATMENT

    Other: STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

Interventions

  • OtherSTOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

    PATIENT WILL STOP USING NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

  • DrugCONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

    PATIENT WILL CONTINUE USING NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

06

What researchers measure

Primary outcomes

  1. Change in Lund Kennedy Score

    Nasal Endoscopy will be performed in the clinic to evaluate the sinonasal cavities using the Lund Kennedy scoring system. The Lund-Kennedy endoscopic score grades the severity of chronic rhinosinusitis (CRS) based on findings from five areas: polyps, discharge, edema, scarring, and crusting, with each graded on a scale of 0 to 2 for each nostril, resulting in a total possible score of 20. A higher score indicates more severe disease.

    Time frame: Baseline, 12 weeks

  2. Change in Pulmonary Function Testing

    PULMONARY FUNCTION TESTING WILL BE PERFORMED WITH THE FEV1/FVC , CALCULATED. A lower score means poorer lung function.

    Time frame: Baseline, 12 weeks

  3. Change in Body Mass Index (BMI)

    BMI will be calculated as weight (kg) / height (m)2

    Time frame: Baseline, 12 weeks

  4. Change in Health Care Utilization

    Health Care Utilization will be measured though a grouped analysis for number of doctor visits, hospital admissions, and number of antibiotics and oral steroid prescriptions.

    Time frame: Baseline, 12 weeks

  5. Change in Sinonasal Outcome Test 22 Questionnaire (SNOT-22) Score

    The SNOT-22 measures nasal symptoms and social/emotional consequences of rhinosinusitis, rated on a scale of 0 (no problem) to 5 (problem is as bad as it can be). Scores may range from 0 to 110, with higher scores indicating worse sinus symptoms

    Time frame: Baseline, 12 weeks

  6. Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score

    The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a disease-specific health-related quality of life (HRQOL) measure for children, adolescents and adults with cystic fibrosis (CF). It is a profile measure of HRQOL with several different domains. The Cystic Fibrosis Questionnaire-Revised (CFQ-R) application calculates the score derived from the CFQ-R, on a 0-100 scale with higher scores indicating better HRQoL.

    Time frame: Baseline, 12 weeks

  7. Change in Patient Health Questionnaire-9 (PHQ-9) Score

    The PHQ-9 measures severity of depression. Potential scores may range from 0 - 27 with higher scores indicating more severe depression.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change in nasal mucous biomarkers.

    A small strip of Leukosorb paper will be placed in the nostril to collect nasal mucous. The strips will be tested for the present of inflammatory markers including IL-4, IL-6, IL-8, TNF-alpha, IL-1B, Neutrophil elastase levels. The presence of inflammatory markers may indicate the return of neutrophilic infiltration.

    Time frame: Baseline, 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 67 phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 39. This study's planned 24 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 30, 2025
StartActual
Jul 2, 2025
Primary completionEst.
Jul 2027was Jul 2026
CompletionEst.
Jul 2027was Jul 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Jul 2027
Nov 10, 2026
Study completion
Jul 2026→Jul 2027
Nov 10, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange in Health Care Utilization: how it is measured was reworded
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Jul 2026→Jul 2027
    Study completion Jul 2026→Jul 2027
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in Health Care Utilization: how it is measured was reworded

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06996951
Lead sponsor
Indiana University
Collaborators
American Rhinologic Society
Responsible party
Elisa Illing (Associate Professor, Indiana University) — Principal investigator
First posted
May 30, 2025
Start date
Jul 2, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Elisa Illing, MD
Contact
eilling@iu.edu
317-944-6467
Elisa Illing, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion